Other Vaccines - Bahrain

Bahrain

Highlights

The revenue in the Other Vaccines market of Bahrain is forecasted to reach US$7.34m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 10.38%, resulting in a market volume of US$12.02m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$24.73bn in 2024.
Bahrain is witnessing an increasing demand for other vaccines, driven by the government's proactive approach to public health and its commitment to vaccination programs.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

Bahrain, a small island nation in the Persian Gulf, is witnessing a growing trend in the Other Vaccines market.

Customer preferences: Bahrain's healthcare system is highly advanced, with a high demand for quality healthcare services. In recent years, there has been a growing awareness among the population regarding the importance of preventive healthcare measures. This has led to an increase in demand for vaccines, including Other Vaccines.

Trends in the market: The Other Vaccines market in Bahrain is witnessing growth due to the increasing prevalence of infectious diseases. The government has been proactive in immunizing the population against various diseases, including influenza, HPV, and meningitis. Additionally, the COVID-19 pandemic has further accelerated the demand for vaccines in the country. Bahrain has been at the forefront of the COVID-19 vaccination drive, with a high vaccination rate compared to other countries in the region.

Local special circumstances: Bahrain is a small country with a high population density, which makes it more susceptible to the spread of infectious diseases. The government has been taking proactive measures to control the spread of diseases, including vaccination drives and awareness campaigns. Additionally, Bahrain is a popular destination for medical tourism, which has further boosted the demand for vaccines.

Underlying macroeconomic factors: Bahrain has a strong economy, with a high per capita income and a well-developed healthcare system. The government has been investing heavily in the healthcare sector, which has led to the development of advanced medical facilities and the availability of quality healthcare services. The country's strategic location in the Persian Gulf and its well-developed infrastructure make it an attractive destination for foreign investors, which has further boosted the healthcare sector.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.